SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Lisinopril Formulation

Manufacturer or supplier's details
Company : MSD
Address : Avenida Tanner de Melo, Quadra 10 Lote 4A, Galpão A Parque Industrial Vice Presidente José Alencar Aparecida de Goias – GO, Brazil
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard
Reproductive toxicity : Category 1A

GHS label elements in accordance with ABNT NBR 14725 Standard
Hazard pictograms :

Signal Word : Danger
Hazard Statements : H360D May damage the unborn child.
Precautionary Statements :
Prevention:
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Storage:
P405 Store locked up.
SAFETY DATA SHEET

Lisinopril Formulation

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>Reproductive toxicity, Category 1A Specific target organ toxicity - repeated exposure (Oral) (Kidney), Category 2</td>
<td>&gt;= 10 &lt;- 20</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td></td>
<td>&gt;= 5 &lt;- 10</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention.
In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact : If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray Alcohol-resistant foam Carbon dioxide (CO2)
Dry chemical

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Carbon oxides
Metal oxides
Oxides of phosphorus

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

If sufficient ventilation is unavailable, use with local exhaust
SAFETY DATA SHEET
Lisinopril Formulation

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>TWA</td>
<td>20 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Wipe limit | 200 µg/100 cm² | Internal |

Engineering measures:
- Minimize workplace exposure concentrations.
- Apply measures to prevent dust explosions.
- Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Respiratory protection:
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type
Hand protection
Material
Remarks
Eye protection
Skin and body protection

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance
Color
Odor
Odor Threshold
pH
Melting point/freezing point
Initial boiling point and boiling range
Flash point
Evaporation rate
Flammability (solid, gas)
Flammability (liquids)
Upper explosion limit / Upper flammability limit
Lower explosion limit / Lower flammability limit
Vapor pressure
Relative vapor density
Density : No data available

Solubility(ies)
  Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
  Viscosity, dynamic : No data available
  Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
  May form explosive dust-air mixture during processing, handling or other means.
  Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
  Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
  Inhalation
  Skin contact
  Ingestion
  Eye contact

Acute toxicity
Not classified based on available information.

Components:

Starch:
Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
SAFETY DATA SHEET
Lisinopril Formulation

SAFETY DATA SHEET
Lisinopril Formulation

Version: 5.1
Revision Date: 01.10.2020
SDS Number: 50009-00015
Date of last issue: 23.03.2020
Date of first issue: 26.01.2015

Acute dermal toxicity: LD50 (Rabbit): > 2.000 mg/kg

**Lisinopril:**
Acute oral toxicity: LD50 (Rat): > 20.000 mg/kg
LD50 (Mouse): > 20.000 mg/kg

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Lisinopril:**
Species: Rabbit
Result: Mild skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Starch:**
Species: Rabbit
Result: No eye irritation

**Lisinopril:**
Species: Rabbit
Result: Mild eye irritation

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Components:**

**Starch:**
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

**Lisinopril:**
Test Type: Maximization Test
Routes of exposure: Dermal
Result: negative
Germ cell mutagenicity
Not classified based on available information.

Components:

Starch:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Lisinopril:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Lisinopril:
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
NOAEL: 90 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
NOAEL: 135 mg/kg body weight
Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

Lisinopril:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 300 mg/kg body weight
Symptoms: No effects on mating performance.
Result: Animal testing did not show any effects on fertility.

**Effects on fetal development**
- **Test Type:** Development
- **Species:** Rat
- **Application Route:** Oral
- **Developmental Toxicity:** LOAEL: 30 mg/kg body weight
- **Result:** positive, No teratogenic effects.

- **Test Type:** Development
- **Species:** Mouse
- **Application Route:** Oral
- **Developmental Toxicity:** LOAEL: 100 mg/kg body weight
- **Symptoms:** Total Resorptions / resorption rate.
- **Result:** Embryotoxic effects and adverse effects on the offspring were detected.

- **Test Type:** Development
- **Species:** Rabbit
- **Application Route:** Oral
- **Developmental Toxicity:** LOAEL: 0,1 mg/kg body weight
- **Result:** Embryotoxic effects and adverse effects on the offspring were detected.

**Reproductive toxicity - Assessment**
Positive evidence of adverse effects on development from human epidemiological studies.

**STOT-single exposure**
Not classified based on available information.

**STOT-repeated exposure**
Not classified based on available information.

**Components:**

**Lisinopril:**
- **Routes of exposure:** Ingestion
- **Target Organs:** Kidney
- **Assessment:** May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Starch:**
- **Species:** Rat
- **NOAEL:** >= 2.000 mg/kg
- **Application Route:** Skin contact
- **Exposure time:** 28 Days
- **Method:** OECD Test Guideline 410

**Lisinopril:**
- **Species:** Rat
LOAEL : < 3.650 mg/kg
Application Route : Oral
Exposure time : 1 y
Target Organs : Kidney

Species : Dog
LOAEL : < 840 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Kidney

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Lisinopril:
Ingestion
Symptoms: Dizziness, Headache, Fatigue, Diarrhea, Nausea, Cough, Lowered blood pressure, electrolyte imbalance
Remarks: May damage the unborn child.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Lisinopril:
Toxicity to daphnia and other aquatic invertebrates
EC50 (Daphnia magna (Water flea)): 20.000 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Persistence and degradability
No data available

Bioaccumulative potential
No data available

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues
Dispose of in accordance with local regulations.

Contaminated packaging
Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
SAFETY DATA SHEET

Lisinopril Formulation

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

ANTT
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

SECTION 16. OTHER INFORMATION

Further information

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA : 8-hour, time-weighted average
SAFETY DATA SHEET

Lisinopril Formulation

Version 5.1
Revision Date: 01.10.2020
SDS Number: 50009-00015
Date of last issue: 23.03.2020
Date of first issue: 26.01.2015

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8